This card is TOTALLY WRONG.
Supportive care is the mainstay of treatment for respiratory syncytial virus (RSV) infection in adults. There are currently no routinely recommended RSV-specific antivirals for immunocompetent adults.
This is mentioned explicitly at a 2024 recent Lancet review: Wildenbeest, J. G., et al. "Respiratory Syncytial Virus Infections in Adults: A Narrative Review." The Lancet Respiratory Medicine, vol. 12, no. 10, 2024, pp. 822–836. https://doi.org/10.1016/S2213-2600(24)00255-8
Regarding Ribavirin: It's rarely used and generally reserved for severely immunocompromised patients (already mentioned in sketchy) with life-threatening disease, but its efficacy in adults remains controversial and is not standard of care.
This is mentioned in The American Society of Transplantation guidlines (2019): Manuel, Oriol, and Meredith Estabrook. “RNA Respiratory Viral Infections in Solid Organ Transplant Recipients: Guidelines From the American Society of Transplantation Infectious Diseases Communi
Source: Society Guidelines - https://pubmed.ncbi.nlm.nih.gov/39265602/













